|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:ATCCode
|
N05CD08
|
|
gptkbp:bioavailability
|
40–50% (oral)
44% (intranasal)
90% (intramuscular)
|
|
gptkbp:brand
|
gptkb:Versed
gptkb:Dormicum
|
|
gptkbp:CASNumber
|
59467-70-8
|
|
gptkbp:color
|
white to light yellow crystalline powder
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:F._Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
1.5–2.5 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C18H13ClFN3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
midazolam
|
|
gptkbp:introducedIn
|
1976
|
|
gptkbp:IUPACName
|
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:MedlinePlusID
|
a609003
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:PubChem_CID
|
4192
CHEMBL685
DB00683
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
intranasal
buccal
|
|
gptkbp:sideEffect
|
gptkb:center
drowsiness
hypotension
respiratory depression
|
|
gptkbp:solubility
|
sparingly soluble in water
|
|
gptkbp:UNII
|
R60L0SM5BC
|
|
gptkbp:usedFor
|
anesthesia induction
sedation
seizure control
anxiety management
|
|
gptkbp:usedIn
|
palliative care
procedural sedation
intensive care sedation
|
|
gptkbp:bfsParent
|
gptkb:Versed
gptkb:CYP3_family
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|